Back to Wells Fargo & Company Wells Fargo & Company

ONCYONCY

Showing 8 of 28 quarters

Position history for Wells Fargo & CompanyWells Fargo & Company's holdings in Oncolytics Biotech Inc.

As of its Q1 2026 13F, Wells Fargo held 6,602 shares of ONCY (Oncolytics Biotech), worth $5,604. Wells Fargo's 13F filings listed ONCY from Q3 2019 to Q1 2026, 27 quarterly filings.

Final Value

$0

Final Shares

0

Total Value Change

-$3,833

Total Shares Change

-4,401

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Exited
0
-100.0%
$00.0%$0.95
0
2026-Q1
Increased
6,602
+22.2%
$5,6040.0%$0.85
13
2025-Q4
Increased
5,401
+22.7%
$4,7200.0%$0.87
12
2025-Q3
Unchanged
4,401
0.0%
$6,1610.0%$1.40
0
2025-Q2
Unchanged
4,401
0.0%
$3,4020.0%$0.77
0
2025-Q1
Unchanged
4,401
0.0%
$2,4200.0%$0.55
0
2024-Q4
Unchanged
4,401
0.0%
$4,0210.0%$0.91
0
2024-Q3
Unchanged
4,401
0.0%
$3,8330.0%$0.87
0

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used